COVID-19 Vaccination Safety in Patients who have had SARS-CoV-2-induced Chilblains


  • Florence Poizeau CHU Rennes
  • Louise Triquet
  • Alain Dupuy Department of Dermatology, and 3Pharmacovigilance Center, University Hospital Rennes, 2 rue Henri le Guilloux, FR-35000 Rennes, France



chilblains, erythromelalgia, vaccine, vaccination, SARS-CoV-2, COVID-19, pernio


Abstract is missing (Short communication)


Download data is not yet available.


Freeman E, McMahon D, Lipoff J, Rosenbach M, Kovarik C, Takeshita J, et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. J Am Acad Dermatol 2020; 83: 486-492. DOI:

Le Cleach L, Dousset L, Assier H, Fourati S, Barbarot S, Boulard C, et al. Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing. Br J Dermatol 2020; 183: 866-874. DOI:

Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, Moreno-Arrones OM, Saceda-Corralo D, Arana-Raja A, et al. Characterization of acute acral skin lesions in nonhospitalized patients: a case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol 2020; 83: e61-63. DOI:

Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183: 71-77. DOI:

Piccolo V, Bassi A, Russo T, Mazzatenta C, Baraldi M, Argenziano G, et al. Chilblain-like lesions and COVID-19: second wave, second outbreak. J Eur Acad Dermatol Venereol 2021; 35: e316-e318. DOI:

Hubiche T, Cardot-Leccia N, Le Duff F, Seitz-Polski B, Giordana P, Chiaverini C, et al. Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic. JAMA Dermatol 2021; 157: 202-206. DOI:

Poizeau F, Oger E, Barbarot S, Le Corre Y, Samimi M, Brenaut E, et al. Chilblains during lockdown are associated with household exposure to SARS-CoV-2. A multicentre case-control study. Clin Microbiol Infect 2022; 28: 285-291. DOI:

Ortega-Quijano D, Fernandez-Nieto D, Jimenez-Cauhe J, Cortes-Cuevas JL, Marcos-Mencia D, Rodriguez-Dominguez M, et al. Association between COVID-19 and chilblains: a case-control study. J Eur Acad Dermatol Venereol 2021; 35: e359-e361. DOI:

McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021; 85: 46-55. DOI:

Grieco T, Maddalena P, Sernicola A, Muharremi R, Basili S, Alvaro D, et al. Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study. Dermatol Ther 2021; 34: e15153. DOI:

Piccolo V, Bassi A, Argenziano G, Mazzatenta C, Cutrone M, Neri I, et al. BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2. J Eur Acad Dermatology Venereol 2021; 35: e493-e494. DOI:

Poizeau F, Barbarot S, Le Corre Y, Brenaut E, Samimi M, Aubert H, et al. The long-term outcome of patients with chilblains associated with SARS-CoV-2. Acta Derm Venereol 2021; 101: adv00614. DOI:

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383: 2603-2615. DOI:

McMahon DE, Kovarik CL, Damsky W, Rosenbach M, Lipoff JB, Tyagi A, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study. J Am Acad Dermatol 2022; 86: 113-121. DOI:

Moghadam P, Frumholtz L, Jaume L, De Masson A, Jachiet M, Begon E, et al. Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain-like lesion during the COVID-19 pandemic. J Eur Acad Dermatol Venereol 2021; 35: e566-e568. DOI:



How to Cite

Poizeau, F., Triquet, L., & Dupuy, A. (2022). COVID-19 Vaccination Safety in Patients who have had SARS-CoV-2-induced Chilblains. Acta Dermato-Venereologica, 102, adv00728.



Short Communication